Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AFMD Affimed	$0.18 -34.9%	$0.40	$0.07 ▼ $5.92	$2.92M	2.07	4.49 million shs	22.99 million shs
BGXX Bright Green		$0.05	$0.03 ▼ $0.54	$11.47M	-0.26	360,154 shs	25,935 shs
CTXR Citius Pharmaceuticals	$1.33 +10.8%	$0.86	$0.65 ▼ $26.25	$12.76M	0.87	696,911 shs	855,333 shs
EQ Equillium	$0.34 +2.0%	$0.39	$0.27 ▼ $1.50	$11.92M	1.94	437,204 shs	133,051 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AFMD Affimed	0.00%	0.00%	0.00%	-76.76%	-96.74%
BGXX Bright Green	0.00%	0.00%	0.00%	+9.09%	-82.29%
CTXR Citius Pharmaceuticals	+10.83%	+45.74%	+87.03%	-14.19%	-91.45%
EQ Equillium	+2.01%	+5.58%	-14.88%	-16.01%	-49.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AFMD Affimed	2.6432 of 5 stars	4.0	0.0	0.0	4.3	0.0	0.0	1.3
BGXX Bright Green	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CTXR Citius Pharmaceuticals	2.6739 of 5 stars	3.4	2.0	0.0	0.0	3.3	0.8	1.3
EQ Equillium	3.4759 of 5 stars	3.2	5.0	0.0	0.0	4.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AFMD Affimed	2.00	Hold	$3.62	1,895.87% Upside
BGXX Bright Green	0.00	N/A	N/A	N/A
CTXR Citius Pharmaceuticals	2.80	Moderate Buy	$54.50	3,997.74% Upside
EQ Equillium	2.33	Hold	$3.00	781.06% Upside

Current Analyst Ratings Breakdown

Latest AFMD, EQ, CTXR, and BGXX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
5/23/2025	CTXR Citius Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/23/2025	CTXR Citius Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/15/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
5/14/2025	AFMD Affimed	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/14/2025	AFMD Affimed	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/13/2025	AFMD Affimed	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/13/2025	AFMD Affimed	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$11.00 ➝ $0.10
5/13/2025	AFMD Affimed	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$5.00 ➝ $0.39
3/28/2025	EQ Equillium	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/28/2025	EQ Equillium	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$3.00 ➝ $1.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AFMD Affimed	$877K	3.33	N/A	N/A	$4.19 per share	0.04
BGXX Bright Green	N/A	N/A	N/A	N/A	$0.06 per share	N/A
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	$10.25 per share	N/A
EQ Equillium	$41.10M	0.30	N/A	N/A	$0.54 per share	0.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AFMD Affimed	-$114.66M	N/A	0.00	N/A	N/A	-7,836.26%	-193.84%	-107.24%	9/1/2025 (Estimated)
BGXX Bright Green	-$13.13M	-$0.06	N/A	N/A	N/A	N/A	-88.37%	-55.30%	N/A
CTXR Citius Pharmaceuticals	-$39.14M	N/A	0.00	1.06	N/A	N/A	-58.63%	-37.67%	8/11/2025 (Estimated)
EQ Equillium	-$8.07M	-$0.39	N/A	N/A	N/A	-19.62%	-74.34%	-46.75%	8/6/2025 (Estimated)

Latest AFMD, EQ, CTXR, and BGXX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/14/2025	Q2 2025	CTXR Citius Pharmaceuticals	-$1.08	-$1.27	-$0.19	-$1.27	N/A	N/A
3/27/2025	Q4 2024	EQ Equillium	-$0.22	-$0.16	+$0.06	-$0.16	N/A	$4.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AFMD Affimed	N/A	N/A	N/A	N/A	N/A
BGXX Bright Green	N/A	N/A	N/A	N/A	N/A
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EQ Equillium	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AFMD Affimed	0.13	1.93	1.93
BGXX Bright Green	N/A	0.01	0.01
CTXR Citius Pharmaceuticals	N/A	0.37	0.06
EQ Equillium	N/A	2.70	2.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AFMD Affimed	30.82%
BGXX Bright Green	7.83%
CTXR Citius Pharmaceuticals	16.88%
EQ Equillium	27.05%

Insider Ownership

Company	Insider Ownership
AFMD Affimed	3.80%
BGXX Bright Green	62.55%
CTXR Citius Pharmaceuticals	10.70%
EQ Equillium	31.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AFMD Affimed	200	16.10 million	15.49 million	Optionable
BGXX Bright Green	2	191.17 million	71.59 million	No Data
CTXR Citius Pharmaceuticals	20	10.63 million	9.50 million	Optionable
EQ Equillium	40	35.72 million	24.43 million	Not Optionable

AFMD, EQ, CTXR, and BGXX Headlines

Recent News About These Companies

Equillium, Inc. (EQ) stock price, news, quote & history - Yahoo Finance

June 26 at 10:11 PM | nz.finance.yahoo.com

4 Emerging Graft versus Host Disease Therapies That Could Change the Treatment Landscape | DelveInsight

June 14, 2025 | medindia.netM

Equillium expands equity incentive plan by 1.78 million shares

May 24, 2025 | investing.com

Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists

May 6, 2025 | finance.yahoo.com

Equillium advancing new AhR modulator

May 3, 2025 | bioworld.comB

Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

May 1, 2025 | finance.yahoo.com

Blood Cancer Data Ignore Sex; Cancer Biosimilars Take Off; Mixed Prevention News

April 26, 2025 | msn.com

Equillium says FDA declines Breakthrough Therapy designation for itolizumab

April 25, 2025 | markets.businessinsider.com

Leerink says Equillium’s itolizumab news ‘disappointing but not surprising’

April 25, 2025 | markets.businessinsider.com

FDA declines itolizumab accelerated approval, says Equillium

April 25, 2025 | thepharmaletter.comT

Equillium shares fall following FDA feedback

April 24, 2025 | in.investing.com

Equillium Announces Feedback from the U.S. Food and Drug Administration

April 24, 2025 | finance.yahoo.com

Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

April 1, 2025 | zacks.com

The week in pharma: action, reaction and insight – week to March 28

March 30, 2025 | thepharmaletter.comT

Equillium downgraded to Market Perform from Outperform at Leerink

March 29, 2025 | markets.businessinsider.com

Equillium reports Q4 EPS (16c) vs. (7c) last year

March 28, 2025 | markets.businessinsider.com

Equillium reports EQUATOR study did not improve complete, overall response rates

March 28, 2025 | markets.businessinsider.com

Equillium Full Year 2024 Earnings: Beats Expectations

March 28, 2025 | finance.yahoo.com

Equillium says graft-versus-host drug fails Phase 3, stock dives

March 27, 2025 | endpts.comE

Itolizumab Shows Long-Term Treatment Benefits in Acute GVHD

March 27, 2025 | curetoday.comC

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
ASML’s AI Edge: How Its EUV Tech Is Creating a New Monopoly
By Jeffrey Neal Johnson | June 10, 2025
View ASML’s AI Edge: How Its EUV Tech Is Creating a New Monopoly
This Banking Giant Just Got a $90 Price Target Upgrade
By Gabriel Osorio-Mazilli | June 6, 2025
View This Banking Giant Just Got a $90 Price Target Upgrade
Why Schwab US Dividend Equity ETF Could Lead the Rotation
By Gabriel Osorio-Mazilli | June 2, 2025
View Why Schwab US Dividend Equity ETF Could Lead the Rotation

AFMD, EQ, CTXR, and BGXX Company Descriptions

Affimed NASDAQ:AFMD

$0.18 -0.10 (-34.95%)

As of 05/19/2025

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Bright Green NASDAQ:BGXX

Bright Green Corporation focuses on the cultivation, manufacture, and sale of cannabis and cannabis-related products. Its products are used in research, pharmaceutical applications, and affiliated exports. The company was incorporated in 2019 and is based in Grants, New Mexico.

Citius Pharmaceuticals NASDAQ:CTXR

$1.33 +0.13 (+10.83%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.35 +0.02 (+1.50%)

As of 04:59 AM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Equillium NASDAQ:EQ

$0.34 +0.01 (+2.01%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$0.34 0.00 (-0.73%)

As of 06/26/2025 07:50 PM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time